Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 2Sarcoma 2Neoplasm Metastasis 2Pancreatic Neoplasms 1Metastatic Solid Tumors 1Malignant Solid Tumour 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumors × DOXO-EMCH × Clear all
NCT01706835 2022-02-10

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡